PFE: FDA Approves IBRANCE
Pfizer's IBRANCE regimen is approved by the FDA for HR+, HER2+ metastatic breast cancer frontline maintenance
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.